Associated Genetic Biomarkers
NCI Definition: A benign or malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma). Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors. 
Solid neoplasms most frequently harbor alterations in TP53, KRAS, PIK3CA, APC, and CDKN2A .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in solid neoplasm .
There are 5 clinical trials for solid neoplasm, of which 2 are open and 3 are completed or closed. Of the trials that contain solid neoplasm as an inclusion criterion, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is no phase specified (0 open).
BRAF is the most frequent gene inclusion criterion for solid neoplasm clinical trials .
Cbl0137, cudc-907, and allogeneic hematopoietic stem cell transplantation are the most common interventions in solid neoplasm clinical trials.
Significant Genes in Solid Neoplasm
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.